



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 22, 2003

Laura L. Frieko 52,920
Name of Attorney or Agent Registration No.
Laura L. Frieko
Signature of Attorney or Agent

Case 7670

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of :
D. N. RUBINGH ET AL. : Confirmation No.: 8554
Serial No.: 09/618,235 : Group Art Unit: 1652
Filed: July 18, 2000 : Examiner: W. W. Moore

For: PROTEASE CONJUGATES HAVING STERICALLY PROTECTED EPITOPE REGIONS
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

(With Certification)

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

☐ 37 C.F.R. §1.97(c) with certification - **After 3 months from filing and after First Office Action but BEFORE Final Action, an action which otherwise closes prosecution, or Notice of Allowance**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicants have not received a final action under §1.113, an action which otherwise closes prosecution, or a notice of allowance under §1.311 as of the date of this submission.

☐ A certification as specified in 37 C.F.R. §1.97(e) is submitted herewith.

08/29/2003 SSESHE1 00000125 162480 09618235

01 FC:1806 180.00 DA

☒ 37 C.F.R. §1.97 (d) with fee and certification - **After 3 months from filing and after Final Office Action or Notice of Allowance, or an action which otherwise closes prosecution, BUT BEFORE Issue Fee paid**

This information disclosure statement, filed under 37 C.F.R. §1.97 (d), is being submitted after receipt of a final action under Section §1.113, or a notice of allowance under Section §1.311, or an action which otherwise closes prosecution, but before (or simultaneously with), the payment of the issue fee.

The Commissioner is hereby authorized to charge payment of the fee under 37 CFR 1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed herewith for this purpose.

☒ Certification under 37 C.F.R. §1.97(e):

☒ (1) I hereby certify that each item of information contained in this information disclosure statement was cited for the first time in any communication in a counterpart application from a foreign patent office, not more than three months prior to the filing of this information disclosure statement

☐ (2) I hereby certify that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement.

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO-1449 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

By Laura L. Frieko
 Laura L. Frieko
 Attorney for Applicants
 Registration No. 52,920
 (513) 626-2721

August 22, 2003
 Customer No. 27752

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-00)


Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

Application Number	09/618,235
Confirmation Number	8554
Filing Date	7/18/2000
First Named Inventor	D N. Rubingh
Group Art Unit	1652
Examiner Name	W. W. Moore
Attorney Docket Number	7670

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	01	WO 91/00345 A1	01/10/1991	Novo Nordisk A/S		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.